Safety of indacaterol, a novel once-daily β2-agonist, in persistent asthma.

被引：0
|
作者：
Yang, W.
Higgins, M.
Cameron, R.
Owen, R.
Yegen, U.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2007年 / 98卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：A79 / A79
页数：1
相关论文
共 50 条
  • [1] Bronchodilator efficacy of indacaterol, a novel once-daily β2-agonist, in patients with persistent asthma
    Pearlman, David S.
    Greos, Leon
    LaForce, Craig
    Orevillo, Chadwick J.
    Owen, Roger
    Higgins, Mark
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2008, 101 (01) : 90 - 95
  • [2] Safety and efficacy of indacaterol, a novel oncedaily β2-agonist, in patients with persistent asthma.
    LaForce, C.
    Aisanov, Z.
    Higgins, M.
    Cameron, R.
    Owen, R.
    Yegen, U.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (01) : A77 - A77
  • [3] Indacaterol, a novel once-daily β2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with persistent
    Kanniess, F
    Cameron, R
    Owen, R
    Higgins, M
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S196 - S197
  • [4] Tolerability of indacaterol, a novel once-daily β2-agonist, in patients with asthma:: a randomized, placebo-controlled, 28-day safety study
    Yang, William H.
    Martinot, Jean Benoit
    Pohunek, Petr
    Beier, Jutta
    Magula, Daniel
    Cameron, Ray
    Owen, Roger
    Higgins, Mark
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 99 (06) : 555 - 561
  • [5] Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily β2-agonist bronchodilator, in subjects with COPD
    Pascoe, S.
    Reynolds, C.
    Pleskow, W.
    Perry, S.
    Hmissi, A.
    Kaiser, G.
    Brookman, L.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (02) : 153 - 161
  • [6] Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD:: A 28-day randomised, placebo controlled clinical trial
    Beier, Jutta
    Chanez, Pascal
    Martinot, Jean-Benoit
    Schreurs, A. J. M.
    Tkacova, Ruzena
    Bao, Weibin
    Jack, Damon
    Higgins, Mark
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2007, 20 (06) : 740 - 749
  • [7] Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting β2-agonist, in different ethnic populations
    Matsushima, Soichiro
    Matthews, Ivan
    Woessner, Ralph
    Pinault, Gregory
    Hara, Hisanori
    Wilkins, Justin
    Sekiguchi, Kaneo
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (08) : 545 - 556
  • [8] Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD
    Dahl, Ronald
    Chung, Kian Fan
    Buhl, Roland
    Magnussen, Helgo
    Nonikov, Vladimir
    Jack, Damon
    Bleasdale, Patricia
    Owen, Roger
    Higgins, Mark
    Kramer, Benjamin
    [J]. THORAX, 2010, 65 (06) : 473 - 479
  • [9] A Dose-Finding Study with the Once-Daily Oral β2-Agonist Bambuterol in Asian Children with Asthma
    A.R. Mendoza
    M. Javier
    J. Ngamphaiboon
    D.Y.T. Goh
    P. Vichyanond
    C.B. Kartasasmita
    M.S. Bautista
    H.I. Boediman
    O.M. Chay
    A.H. Omar
    C. Badcock
    H. Olsson
    [J]. Clinical Drug Investigation, 1999, 18 : 369 - 375
  • [10] A dose-finding study with the once-daily oral β2-agonist bambuterol in Asian children with asthma
    Mendoza, AR
    Javier, M
    Ngamphaiboon, J
    Goh, DYT
    Vichyanond, P
    Kartasasmita, CB
    Bautista, MS
    Boediman, HI
    Chay, OM
    Omar, AH
    Badcock, C
    Olsson, H
    [J]. CLINICAL DRUG INVESTIGATION, 1999, 18 (05) : 369 - 375
12345